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Abstract 
Tuberculosis (TB) and human immunodeficiency virus (HIV) co-epidemics form a huge burden of disease in the Southeast Asia region. Five 
out of eleven nations in this region are high TB/HIV burden countries: Myanmar, Thailand, India, Indonesia and Nepal. The trends of TB 
incidence in these countries have been rising in recent years, in contrast to a falling global trend. Experts in the field of TB control and health 
service providers have been perplexed by the association of TB and HIV infections which causes a mosaic clinical presentation, a unique 
course with poor treatment outcomes including death. We conducted a review of contemporary evidence relating to TB/HIV control with the 
aims of assisting integrated health system responses in Southeast Asia and demystifying current evidence to facilitate translating it into 
practice. 
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Introduction 
Tuberculosis (TB), a centuries-old disease, causes 
more than a million deaths every year. After World 
War II, TB was well-controlled globally with TB 
mortality declining dramatically [1]. However, it re-
emerged after the 1980s following the global outbreak 
of the human immunodeficiency virus (HIV) infection 
[1].  A large number of HIV-infected individuals were 
rapidly killed by TB in high TB burden settings such 
as Africa and Thailand, as well as its neighboring 
countries in Southeast Asia [1-3]. The World Health 
Organization (WHO) declared TB a global health 
emergency in 1993. Afterward, global and national 
responses were launched progressively but 
heterogeneously across the countries with differing 
resources and health systems.  
Today, TB remains a disease which is highly 
infectious, difficult to diagnose, and slow to treat. Its 
treatment and curability by multiple-combination 
chemotherapy is being challenged by an increase in 
drug resistance worldwide [2]. The technical 
knowledge of TB control has been hindered by the 
association of TB and HIV infections which causes a 
mosaic clinical presentation, a unique course and poor 
treatment outcomes including death. 
In this review, both conclusive and inconclusive 
evidence was appraised in terms of epidemiology, 
diagnosis, pathophysiology, treatment, and prevention 
of TB/HIV co-infection. It was aimed to identify the 
gaps in research and integrated health system 
responses in Southeast Asia, catalyzing translation of 
contemporary evidence to practice. 
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TB/HIV regional epidemiology in Southeast 
Asia 
Globally the trend of TB burden has been falling in 
the last few years, but this scenario is being threatened 
by TB/HIV co-epidemics. The World Health 
Organization (WHO) estimated that in 2010 the global 
burden of TB cases stood at 8.8 million, while 34 
million people were living with HIV and 1.1 million 
were TB/HIV co-infected patients [2,4]. TB/HIV co-
infection caused 500,000 deaths worldwide in 2008, 
380,000 deaths in 2009 and 350,000 deaths in 2010 
[5]. The burden of these two diseases is highest in 
Africa followed by Southeast Asia. Southeast Asia is 
home to 3.5 million people living with HIV (PLWH) 
and 5 million TB patients, which represents 41% of 
global TB patients. Five out of eleven nations in the 
Southeast Asia region are high TB/HIV burden 
countries: India, Indonesia, Myanmar, Nepal and 
Thailand [6]. Neighboring countries such as Cambodia 
and Vietnam are also relatively high TB/HIV burden 
countries. The WHO estimated that HIV prevalence in 
Southeast Asia was 0.3%, while HIV prevalence 
among TB patients was 5.7% [4]. However; the 
burden of TB/HIV co-infection in the Southeast Asia 
region is heterogeneous across the 11 countries 
(Figure 1). PLWH residing in high TB prevalent 
countries experience infection and reinfection of 
Mycobacterium tuberculosis (M. tuberculosis) 
resulting in a large number of TB/HIV co-infected 
patients and high consequent mortality. Such 
incidence of HIV-associated TB is highest in 
Myanmar, followed by Thailand, India, and Indonesia 
[4]. Moreover, the TB incidence in those countries has 
been rising in recent years, compared to a falling 
global trend [3,7].    
 
Immunopathology of TB/HIV co-infection 
Insight into the immunopathological 
interrelationship between these two severe diseases 
has been explained by many observational and 
interventional studies over the last three decades 
[6,8,9]. HIV-infected individuals are more susceptible 
to TB infection from a new source than HIV-negative 
individuals. Persons co-infected with TB and HIV are 
21 to 34 times more likely to develop active TB 
disease than persons without HIV [5]. Moreover, the 
incidence of severe and extra-pulmonary TB, such as 
TB meningitis, and death rate are higher in HIV-
infected patients. The natural course of TB has been 
exacerbated by the HIV manipulated immunological 
reaction against TB, affecting macrophage function, 
cytokine production, and failure to contain initial or 
 
Figure 1. HIV prevalence (deep red line) and HIV prevalence among TB cases (blue bars)  
in WHO Southeast Asia Region 
Data Source: Country reports, national AIDS programmes; Global TB Control WHO Report, 2011 
Note: Figures are rounded off.  Data shown are the best available estimates. Data not available for DPR Korea. 
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latent M. tuberculosis infection and disruption of 
granuloma. Several hypotheses have been proposed to 
explain how HIV increases the risk of TB infection 
and how M. tuberculosis infection may exacerbate 
HIV infection, but the exact mechanism is still poorly 
understood [9]. 
Granuloma, the major hallmark of the human 
immune response to TB, is a structure composed of 
macrophages, lymphocytes, dendritic cells, 
neutrophils, and sometimes fibroblasts, often with a 
necrotic center. It serves optimal immunologic 
functions to contain the M. tuberculosis bacilli and 
acts as an immune microenvironment for cellular 
interactions that limit M. tuberculosis replication. HIV 
co-infection disrupts the granuloma structurally and 
functionally [9]. The exacerbated pathology of TB in 
patients with HIV infection is probably due to 
qualitative (functional) and quantitative changes in 
immune response against M. tuberculosis, especially 
inside the granulomas [9]. 
 
Quantitative changes 
HIV replication is increased at sites of M. 
tuberculosis infection leading to an exacerbated 
pathological process. Several studies that measured 
HIV levels in lungs, pleural cavities, and the 
associated macrophages observed an increased HIV 
replication at sites of M. tuberculosis infection. Nakata 
et al. (1997) showed that there are greater HIV p24 
levels and viral loads in bronco alveolar lavage fluid 
(BAL) from TB-involved lungs than in BAL fluid 
from TB uninvolved lungs [8].  
HIV induces primary or reactivated TB through 
the killing of CD4+ T cells within granulomas. CD4+ T 
cells play a major role in controlling the virulence of 
M. tuberculosis inside and outside the granulomas. 
Lawn et al. showed that the HIV-infected individuals 
with fewer peripheral CD4+ T cells are more prone to 
TB than HIV-infected individuals with relatively 
higher CD4+ T cells [10]. Furthermore, the study of 
Diedrich et al. reported that the reactivation of latent 
M. tuberculosis in cynomolgus macaques infected 
with simian immunodeficiency virus (SIV) is 
associated with early peripheral T cell depletion even 
before the rise in SIV viral load [11]. 
 
Qualitative changes 
The killing mechanisms of macrophage containing 
M. tuberculosis are manipulated by HIV co-infection. 
Macrophages are major compartments of human 
innate immunity in containing M. tuberculosis 
infection. HIV and M. tuberculosis co-infected 
macrophages induce less tumor necrosis factor (TNF)-
dependent apoptosis than macrophages infected with 
only M. tuberculosis [12]. Moreover, co-infected 
macrophages release less TNF than macrophages 
infected with only M. tuberculosis [12]. Revealing 
another aspect of functional changes in macrophages, 
Deretic et al. showed that HIV further decreases the 
ability of M. tuberculosis-infected macrophages to 
acidify vesicles [13]. 
HIV induces functional changes in M. 
tuberculosis-specific T cells. Apart from killing M. 
tuberculosis-specific T cells, HIV infection induces 
some functional changes in those cells decreasing their 
ability to contain M. tuberculosis. Geldmacher et al., 
in their studies, observed fewer interferon-gamma 
(IFN-γ+)-producing M. tuberculosis-specific memory 
CD4+ T cells after HIV infection in individuals with 
latent TB [14].  
Additionally, HIV exerts its adverse effects by 
interfering with the cell cycle [15]. The virus lowers 
IFN-γ mRNA production and therefore cellular 
proliferation in airways of patients with AIDS and TB 
as opposed to individuals with TB alone [15]. These 
findings were further enhanced by the observations of 
lower IFN-γ, TNF, and interleukin 2 (IL-2) production 
and cellular proliferation in M. tuberculosis-specific 
peripheral T cells in HIV-positive individuals  as 
opposed to HIV-negative individuals with active TB 
[16]. Overall, the immune pathological understanding 
of TB/HIV co-infection has improved to explain the 
more severe and silent course of the two diseases in 
one host, but is still in the evolution phase in terms of 
applying improved diagnosis and treatment. 
 
Diagnosis of active TB disease in HIV-infected 
persons 
TB diagnosis has never been easy and 
straightforward, especially in HIV-infected patients, 
and it cannot be made by a single diagnosis test. A 
physician’s decision, based on a clinical work-up of 
symptoms, chest X-ray (CXR), and sputum smear 
microscopic examination, triggers the TB treatment at 
district level hospitals within the developing setting of 
Southeast Asia, where culture is usually not included 
in the routine diagnosis algorithm [17]. Recently, the 
WHO-recommended TB diagnosis models were 
compared in HIV-infected TB suspects, in terms of 
cost effectiveness, to reduce the mortality within 6 
months of antiretroviral therapy (ART) initiation [18]. 
The GeneXpert algorithm was found to be less costly 
than either smear-CXR or smear-CXR-culture 
algorithms. Culture and GeneXpert algorithms were 
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more cost effective in reducing mortality than the 
current practice [18] (Table). This report represented a 
new diagnostic outline, skipping traditional diagnosis 
methods, which is likely to save time and resources. 
 
Algorithm for TB diagnosis in people living with HIV  
In recent years, TB diagnosis research has been 
conducted worldwide. However, studies done in 
Southeast Asia followed the diagnostic algorithm 
approach, which reinvented the traditional clinical 
parameters of ruling out active TB in order to start 
ART or to provide isoniazid preventive therapy (IPT) 
in a program approach. The WHO 2007 algorithm for 
TB diagnosis in HIV patients was evaluated in 
Cambodia during 2008-2009 [19]. The median time to 
TB treatment initiation was 5 days (interquartile range, 
IQR: 2–13 days), ranging from 2 days (IQR: 1–11.5 
days) for extra-pulmonary TB, over 2.5 days (IQR: 1–
4 days) for smear-positive pulmonary TB, to 9 days 
(IQR: 3–17 days) for smear-negative pulmonary TB 
[19]. However, the sensitivity of the algorithm was 
very low (58.8%) despite its inclusion of no cough or 
cough less than two weeks as a criterion in suspects 
with constitutional symptoms or abnormal chest X-
ray. In 2010, Cain et al. evaluated another algorithm, 
applying cough for any duration and other symptoms 
such as fever, night sweats and loss of appetite, as a 
way of identifying TB in PLWH (median CD4 count 
of 242 cells/mm3) in three countries: Thailand, 
Vietnam and Cambodia. The sensitivity of the 
algorithm was improved to 88% [20]. The authors 
suggested that patients lacking these symptoms could 
be candidates for IPT, although a small proportion, 
about 3%, might have active TB and be undertreated 
[20]. These studies changed the paradigm of cough 
“for more than two weeks” to be cough “for any 
duration” when screening TB among PLWH. 
 
Current gold standard diagnostic tests  
The sputum smear microscopic examination of 
acid fast bacilli (AFB), discovered more than 125 
years ago, still remains the mainstay bacteriological 
TB diagnosis test in Southeast Asia, where more than 
half of the reported TB incident cases were smear 
AFB negative [7]. Mycobacterial culture is the current 
gold standard diagnostic test for TB diagnosis. 
However, the solid culture testing system is time-
consuming, while the liquid culture testing system is 
expensive and not feasible in the Southeast Asia 
setting, except in tertiary care hospitals [21]. Adding 
these tests to symptoms screening and chest X-ray 
increases the level of TB case detection. However, 
smear-negative TB is highly prevalent among PLWH 
and atypical presentation of chest radiography and 
silent clinical features are not uncommon in immune-
compromised patients with a very low CD4 count.  
 
 
 
 
Table. The cost of three TB diagnostic algorithms for newly initiated ART among PLWH who manifest  
either current cough, fever, night sweats, or weight loss at the initiation of ART, South Africa, 2011† [18] 
Algorithm 
components 
Current practice WHO-recommended practice 
with culture 
WHO-recommended practice 
with Xpert MTB/RIF 
Sputum smear* + - - + - - - 
  
Chest X-Ray 
 
+ - 
 
+ - - 
  
TB Cultureα 
     
+ - 
  
Xpert MTB/RIF 
       
+ - 
TB treatment yes yes no yes yes yes no yes no 
Cost per TB 
case detected   
$10 /patient $22 /patient $25 /patient 
Detection rate  70 cases per 1000 patients 
initiating ART 
86 cases per 1000 patients 
initiating ART 
78 cases per 1000 patients 
initiating ART 
Cost for ART 
initiation#  
$850 /patient $879 /patient $809 /patient 
† ART, antiretroviral therapy; PLWH, people living with HIV; RIF, rifampicin. 
* Sputum smear using 2 specimens. 
α 1 sputum Mycobacterial culture using the automated Mycobacteria Growth Indicator Tube (MGIT).  
# Unit cost of TB diagnosis and treatment and ART costs. 
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Nucleic acid amplification tests (NAATs) 
NAATs are rapid TB diagnostic tests, which are 
faster than both smear microscopy and culture. Former 
generation NAATs were not sensitive enough for the 
effective TB screening. However, newer NAATs have 
increased the case detection rate of smear-negative TB 
among HIV-positive patients within high prevalent 
HIV settings.  Establishment costs and human resource 
needs formed significant barriers, meaning that the 
diagnosis of TB among HIV-infected people remained 
a challenge in the resource-poor Southeast Asian 
setting. Recently, the WHO started to implement 
application of the GeneXpert machine and or the Xpert 
MTB/RIF assay (Cepheid, Sunnyvale, CA, USA). It is 
a cartridge-based fully automated NAAT for TB 
diagnosis and rifampicin resistance testing [22]. It 
purifies concentrates, amplifies by rapid real-time 
PCR assay, and identifies targeted nucleic acid 
sequences in the TB genome from unprocessed 
sputum samples and offers TB diagnosis within two 
hours, with minimal hands-on technical time. The 
sensitivity in detecting smear-negative culture-positive 
TB patients is 72.5% [22]. It is suitable for use in TB 
and HIV disease-endemic countries. All eleven 
countries in Southeast Asia have ordered at least one 
GeneXpert instrument according to the WHO 
monitoring of GeneXpert implementation as of 2012 
[23]. 
 
Microscopic observation drug susceptibility assay 
(MODS) 
The microscopic observation drug susceptibility 
assay (MODS), first evaluated in Peru,  is a well-
known, low-cost and low-technical direct culture 
method, providing TB diagnosis and drug 
susceptibility results in 7 to 14 days [24]. It has been 
evaluated in Asian countries such as Thailand and 
Vietnam with variable results [17,25]. The TB 
diagnosis performance of MODS in HIV-positive 
patients was promising, but the sensitivity for smear-
negative cases was weak at 38% [26]. However, 
MODS identified TB meningitis in cerebrospinal fluid 
samples with a very high accuracy (positive predictive 
value 100% and negative predictive value 78.7%) as 
well as at a low cost of 0.53 US$ per sample [25].  
 
Serological tests   
The commercial serological tests can mislead 
diagnosis and increase costs. After twelve months of 
rigorous analysis by global experts involving 
evaluation of evidence from 67 studies for pulmonary 
TB and 27 studies for extra-pulmonary TB, the WHO 
issued an explicit “negative” policy recommendation 
to stop the use of serological tests for TB [27].  
 
Urine tests 
Detection of TB-specific biomarkers, namely 
Lipoarabinomannan (LAM), in the urine is an 
alternative diagnostic option. A newer invention, the 
LAM strip test offers an easy-to-perform bedside TB 
diagnosis for PLWH with a very low CD4 count (< 
200 cells/m3) and most at risk of mortality [28]. Active 
TB cases were diagnosed at bedside within 25 minutes 
and at a cost of 3.5 US$ per test. The sensitivity and 
specificity were 66% and 96%, respectively. It could 
serve as a “point of care” TB diagnosis test in 
advanced immunocompromised patients. These 
performance characteristics indicated the possibility to 
rule in TB among PLWH with low immune status in 
the Southeast Asia setting. A newer sandwich 
immunoassay, to detect the LAM and other 
biomarkers in complex patients’ samples, is being 
developed but has yet to be evaluated. Many other new 
tests are still in the TB diagnostic research pipeline, in 
the form of single tests or parts of algorithms, in the 
ongoing challenge of TB diagnosis. 
 
Treatment of active TB disease in HIV-infected 
persons 
There are three main options for the treatment of 
HIV-associated TB in the developing setting of 
Southeast Asia: 1. TB therapy, involving a 
combination of 4 to 6 anti-TB drugs; 2. antiretroviral 
therapy, with at least 3 antivirals; and 3. therapy using 
other drugs for prevention of opportunistic infections, 
such as fluconazole and co-trimoxazole preventive 
therapies in cases of immunodeficiency. 
 
Timing of ART and TB treatment  
The optimal timing for initiation of ART 
antiretroviral drugs, in relation to TB therapy, 
remained unclear until 2010. The pros and cons were 
the survival benefit and the risk of immune 
reconstitution inflammatory syndrome (IRIS), 
respectively. Afterward, three clinical trials, namely 
SAPiT, STRIDE and CAMELIA, conclusively 
confirmed the substantial survival benefit in early 
initiated ART [29-31]. Mortality was highest in 
sequential ART, i.e., starting ART after the 
completion of TB treatment [29]. ART initiated during 
TB therapy reduced the mortality rate in all three trials 
[29-31]. How early to begin ART during TB therapy 
should be judged by the level of immune deficiency 
according to the CD4+ T cell count of the patients. 
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Among patients with CD4+ T-cell counts less than 50 
cells/mm3, ART initiated two weeks after the 
commencement of TB treatment is beneficial in 
reducing AIDS-defining illnesses and death (hazard 
ratio 0.62, 95% CI 0.44 to 0.86. P = 0.006), and 
outweighs the risk for IRIS [30,31]. In a clinical trial 
in Cambodia, the same survival benefit of early ART 
was reported among patients with CD4+ T cell counts 
less than 50 cells/mm3 and CD4+ T cell counts  
between 51-200 cells/mm3 [31]. The goal of early 
ART initiation is to shorten the time that the patient 
has profound immunodeficiency. 
ART initiated in patients after two weeks of TB 
treatment reduced mortality rate by 41.7%, compared 
to those who started ART after 8 to 12 weeks. Even a 
brief delay made a huge difference. Recent trial results 
in Thailand could not find any significant difference 
when comparing ART initiated in patients after four 
weeks compared with ART started in patients at 12 
weeks [32]. However, a brief delay in starting ART 4 
to 8 weeks after the initiation of TB therapy in patients 
with CD4+ T cell counts more than 200 cells/mm3 did 
not convey any increase in the risk of a new AIDS-
defining illness or death, with a reduced risk of IRIS 
[29]. Moreover, immunological studies revealed that 
delaying the initiation of ART for up to 12 months 
during complete treatment of pulmonary TB among 
PLWH with preserved CD4+ T cells greater than 350 
cells/mm3 may not accelerate a decline in 
immunologic function [33]. However, the current 
WHO 2010 ART guideline recommends initiating 
ART in TB/HIV co-infected patients irrespectively of 
the CD4 count.  
Underpinning the implementation of this 
consolidated evidence was an integration of health-
care management of TB and HIV clinics which can 
provide a CD4 test and TB diagnosis to TB-suspected 
PLWH within two weeks concomitantly. Another 
point of view is to consider the influence of the TB 
site on mortality. All the studies described above 
recruited pulmonary TB patients. The incidence of 
extra-pulmonary TB was increasingly common among 
the Asian TB/HIV cohort and was associated with 
higher mortality [34]. A randomized control trial of 
HIV-associated TB meningitis in Vietnam reported a 
very high mortality rate (59.8% and 55.6 %) regardless 
of whether ART started within seven days or after two 
months following the start of TB treatment. The 
treatment outcome was not significantly different in 
relation to the timing of ART initiation [35]. Better 
therapeutic options are needed for HIV-associated 
extra-pulmonary TB patients, especially those with 
meningitis.  
Despite the clinical trials results showing that 
survival benefit outweighed the adverse effect, the 
practicality of those regimens could be weakened by 
other factors such as common drug-drug interactions, 
side effects, pill burden, and the patient’s compliance 
[6]. Anti-TB drug-induced hepatotoxicity is common. 
Interaction between anti-TB and highly active 
antiretroviral therapy (HAART) can cause failure in 
either treatment. Still, it is difficult to predict 
hepatotoxicity during TB treatment. Moreover, 
directly observed treatment, short-course (DOTS) 
strategy, the well-known compliance enhancer in a TB 
control program, has not been evaluated in relation to 
integrated TB/HIV treatment. 
 
Treatment of latent infection for preventing TB 
in HIV-infected persons  
Before the HIV epidemic, the Bacille Calmette-
Guérin (BCG) vaccine could prevent the fatal forms of 
TB, namely meningitis and disseminated TB. 
However, there is no currently effective vaccine to 
prevent all forms of TB in PLWH. A newer TB 
vaccine is still in trial. Meanwhile, preventing active 
TB among PLWH, in other words, treating latent TB 
infection (TLTI) to prevent active TB, is an attractive 
alternative strategy. Currently, it is one of the 
constituents in the WHO’s TB preventive strategies, 
namely the 3Is: 1. intensive case finding; 2. infection 
control; and 3, Isoniazid preventive therapy (IPT). IPT 
could make a difference in reducing the incidence of 
TB among PLWH and consequently offer a survival 
benefit to PLWH. 
 
TLTI or efficacy of IPT reducing TB incidence among 
PLWH 
IPT reduced the TB incidence among PLWH 
before and in the ART era. According to Cochrane’s 
review of 12 randomized clinical trials (RCTs) in the 
pre-ART era [36], TB incidence in IPT-treated PLWH 
was 3% compared to 6% in the placebo group. 
Overall, IPT reduced the risk of active TB by 33% 
(relative risk 0.67, 95% CI 0.54 to 0.85). Among 
tuberculin skin test (TST) positive PLWH, TB 
incidence after receiving IPT was 2% compared to 7% 
in the placebo group, and IPT reduced the risk of 
active TB by 64% (relative risk 0.36, 95% CI 0.25 to 
0.57). TB incidence among TST-negative HIV patients 
after receiving IPT was 3.8%, compared to 4.5% in the 
placebo group. IPT reduced the risk of active TB by 
14% (relative risk 0.86, 95% CI 0.59 to 1.26) in TST-
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negative PLWH. The effect of IPT in the ART era was 
also reported by a prospective cohort study in a high 
TB burden setting of Africa: in that study, the risk of 
TB was drastically reduced (89%) by IPT in PLWH 
receiving ART, and TB incidence was lowest among 
those who received IPT preceding ART when 
compared to those who received only ART or those 
received only IPT [37].  
 
Efficacy of IPT offering survival benefit among PLWH 
IPT might also benefit the survival of PLWH as 
treating latent infection can prevent the drastic 
immune-deficiency triggered by active TB in HIV-
infected hosts. In 2010, a study in South Africa 
compared the reduction of death in the ART cohorts in 
12 months of follow-up and revealed a significantly 
longer survival time in IPT-treated than non IPT-
treated groups [38]. IPT reduced the mortality of 
PLWH when provided with or before ART initiation 
[38]. Recently, a non-randomized comparative study 
in Thailand reported the impact of TST guided IPT on 
four-year follow up. TB incidence was significantly 
lower among PLWH attending the hospital with TST-
guided IPT provision than among patients attending 
the hospital without it [39]. In contrast to the African 
report, Khawcharoenporn et al. reported that the 
mortality in IPT-treated and non IPT-treated cohorts 
were similar [39]. Those two studies were different in 
terms of IPT provision protocol, sample size, and the 
higher TB prevalence in Africa. A randomized trial in 
a Southeast Asian setting may give a conclusive 
answer. 
 Despite the convincing evidence cited above, IPT 
reached only 12% of eligible HIV patients globally in 
2010 [2]. In the Southeast Asia region, only 4 of 11 
countries implemented and reported the provision of 
IPT in 2009 [40]. Most of the countries in Southeast 
Asia did not include IPT in their national guidelines, 
according to WHO TB/HIV collaborative activities, 
although IPT was provided in Bhutan and Thailand 
[7]. One of the challenges underlying this sluggish 
roll-out was the difficulty in diagnosing patients with 
latent tuberculosis among PLWH as candidates for 
IPT [40]. 
 
Identification of latent infection in HIV-
infected persons  
To identify the HIV-infected individual who could 
benefit from IPT, tests to diagnose latent tuberculosis 
infection (LTBI) and their performance characteristics 
in high TB burden settings are to be determined. Since 
there is no gold standard for the diagnosis of LTBI, it 
is challenging to diagnose LTBI. Until recently, the 
tuberculin skin test (TST) has been the sole diagnostic 
for LTBI. As the TST is based on delayed-type 
hypersensitivity response mediated by lymphocytes, 
especially T cells after injection of a purified protein 
derivative (PPD), the sensitivity of the TST in the 
HIV-infected population is highly reduced due to 
immune suppression [41]. In addition, TST is also 
known to be confounded by prior BCG vaccination or 
infection of non-tuberculous mycobacterium (NTM) 
due to cross-reactivity of antigens, which are common 
in HIV-endemic areas [42]. 
 In the last decade, interferon-gamma (IFN-γ) 
release assays (IGRAs) were developed for diagnosing 
LTBI. IGRAs detect the release of IFN-γ in response 
to highly M. tuberculosis-specific antigens, such as 
early-secreted antigen 6 (ESAT-6) and culture filtrate 
protein 10 (CFP-10), which are absent from all BCG 
vaccine strains and most of the non-tuberculous 
mycobacteria (NTM) [43]. Currently, two types of 
IGRAs are commercially available. One of the IGRAs, 
QuantiFERON-TB Gold In-Tube (QFT, Cellestis Ltd., 
Victoria, Australia) is based on the ELISA assay and 
uses whole blood for antigen stimulation. QFT 
contains an additional M. tuberculosis-specific 
antigen, TB7.7 in addition to ESAT-6 and CFP-10. 
Another IGRA, T-SPOT.TB (T-SPOT, Oxford 
Immunotec Ltd., Abingdon, UK), is based on the 
Enzyme-Linked ImmunoSpot (ELISPOT) Assay and 
uses purified peripheral blood mononuclear cells 
(PBMCs) for antigen stimulation. As IGRAs stimulate 
antigen-specific T cells with M. tuberculosis specific 
antigens, it has been demonstrated that IGRAs have 
higher specificity than TST among BCG-vaccinated 
populations [44]. IGRAs have also been shown to 
have higher sensitivity than TST [44]. Since their 
development, IGRAs have been well accepted in many 
developed countries and incorporated into their TB 
programs. The advantages of IGRAs over TST include 
not only higher specificity, but avoidance of a second 
visit, objective test results, and booster effect. 
However, it would be important to note that IGRAs do 
have some limitations [45]. Specifically, IGRAs 
cannot distinguish between active TB and LTBI, or 
recent infection and remote infection [43].  As IGRAs 
measure immune responses against M. tuberculosis 
infection, as the TST does, the sensitivity of IGRAs in 
HIV-infected populations also decreases [46]. 
Although the count of CD4+ T cells decreases with the 
progression of HIV infection, which could affect the 
sensitivity of IGRAs, it has been reported that IGRAs 
generally perform better among HIV-infected 
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populations compared to TST [47]. Because QFT uses 
whole blood regardless of lymphocyte count, and T-
SPOT uses a certain count of PBMCs, the sensitivity 
of QFT is supposed to be lower than that of T-SPOT 
in the HIV-infected population. Furthermore, IFN-γ 
response to mitogen (the positive control) in QFT was 
proportionate to the CD4+ T cell counts in PLWH with 
CD4 counts less than 50 cells/ul. Thus fewer IFN-γ+-
producing M. tuberculosis-specific memory CD4+ T 
cells in PLWH with latent TB lead to poor sensitivity 
of QFT [14,48]. In fact, several studies have shown 
that the responses of T-SPOT are well retained even in 
HIV-infected populations, whereas those of QFT, as 
well as TST, decrease as the count of CD4+ T cells 
declines [49]. Therefore, the best available diagnostic 
test for LTBI in HIV-infected populations, at present, 
appears to be T-SPOT; however, it is important to 
improve the diagnostic accuracy. More recently, it has 
been reported that combining TST and T-SPOT 
increases the diagnostic sensitivity in HIV-infected 
individuals [50]. Another approach to improve the 
sensitivity of LTBI diagnosis is to search for other 
potential biomarkers, such as IFN-γ inducible protein 
10 (IP-10). 
Numerous studies have been undertaken since the 
development of IGRAs, showing them to be superior 
to TST in diagnosing LTBI. So far, it is not conclusive 
whether the use of IGRAs improves the identification 
of PLWH who could benefit from IPT. Further studies 
are needed to investigate how to optimize the 
performance of IGRAs in PLWH, especially in 
Southeast Asian settings where most of the PLWH 
have been BCG vaccinated and IGRAs were 
underutilized.  
The current WHO-recommended approach for 
resource-limited settings is to screen PLWH for active 
TB using a clinical algorithm of four symptoms 
(current fever, cough, weight loss, and night sweats) 
and to provide IPT to those who are negative on 
screening [51]. The negative predictive value of this 
type of algorithm is 97.7% (95% CI 97.4–98.0) in 
places with 5% TB prevalence among PLWH to rule 
out active TB [51]. The risk of active TB 
misdiagnosed as LTBI is minimal. Further studies are 
necessary to evaluate the implementation and impact 
of this guideline and its barriers in Southeast Asia. 
 
Evidence to implementation: health service 
delivery models  
The WHO advocated collaborative TB/HIV 
control activities years ago. Integrated collaboration is 
a challenge in most of the Southeast Asian nations. 
Early provision of ART in TB/HIV co-infected 
patients is evidence-based and supported by consistent 
guidelines. To translate these evidence-based 
guidelines into practice, countries need an adequately 
funded health system with a highly integrative health-
care delivery service model [52]. To initiate ART 
services for HIV-infected active TB patients, a one-
stop service that provides the basic diagnostic needs to 
confirm TB diagnosis, HIV tests, and CD4 counts is 
required. It demands a close collaboration between TB 
and HIV programs and health service providers. The 
best model for a TB/HIV health-care delivery service 
provides services from the national level to catchment 
area community hospitals. A study of three health-care 
service models in Malawi is worth reiterating (Figure 
2) [52]: 1. in the referral based model, TB and HIV 
clinics refer the patients for each service; 2. in the 
partially integrated models, a synchronized service of 
TB and HIV clinics for TB/HIV patients is offered; 
and 3. in the integrated models, all TB and HIV/AIDS 
services (HIV counselling as well as ART and TB 
treatment) are provided at the same clinic or the same, 
one-stop shop. 
Current clinics in Thailand are mostly based on 
either model 1 or 2. The experience in Malawi has 
shown model 3 as the best cost-effective model that 
improves the patients’ outcome [52]. Barriers to 
patient care such as a long distance to travel between 
HIV and TB clinics, a limited budget for ART, health 
care providers’ delay, and a lack of a universal 
coverage system may possibly result in a delay in 
implementing the recommended guidelines for 
treatment. Moreover, a politically committed health 
system, well-funded for diagnostic and treatment 
services, is essential. It requires facilities for testing 
HIV and the CD4 count, as well as TB diagnostics and 
facilities for DOTS.  Practically, indecisive clinical 
presentations, such as coughless TB, smear-negative 
TB, and high CD4 counts require a skillful physician 
to assess the patient and come to a clinical decision; 
however, this is hardly possible in catchment area 
clinics at the community level of developing countries. 
Where the diagnostics of TB such as culture 
systems are lacking and where a physician to start TB 
treatment in query cases is not feasible, delayed 
referrals, under-diagnosis and consequent further 
transmission of TB, resulting in poor outcome for 
patients, will still occur in the resource-poor setting. 
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To resolve these realities in developing nations in 
Southeast Asia, health-care providers at the 
community level must be trained to proceed with a 
high index of TB suspicion among PLWH, to enable 
appropriate urgent referral for treatment with sensitive 
and easily applicable TB diagnostic testing, such as 
GeneXpert or LAM strip tests. 
Recently, a multinational analysis showed that 
every US$100 per capita government health 
expenditure was associated with a 33% (95% CI: 
24%–42%) decrease in TB/HIV mortality rates [53]. 
Implementing wider access to ART in a TB/HIV 
burden country needs huge financial resources. Access 
to ART is very difficult for PLWH in countries with 
the “out of the pocket” payment system such as the 
one in Myanmar.  Therefore, a mechanism for 
mobilizing the national budget, as well as effective 
external support, through faster and proper entry 
points, is required. 
 
Research gaps in awareness studies 
TB was a well-known disease in the past and it is 
re-emerging as a common epidemic disease, globally. 
The awareness and knowledge of TB among the 
persons at most risk, such as PLWH, is very important 
in preventing the transmission of infection and needs 
immediate attention today [54] There have not been 
many studies assessing such awareness. A decline in 
TB incidence and mortality before World War I 
preceded the discovery of drugs and vaccines [1]. This 
was a historically evident example of health promotion 
via public awareness, which uplifted general well-
being and reduced TB incidence. It would be 
beneficial to assess the awareness and knowledge of 
TB among PLWH and their family members, in order 
to deliver health education that can promote awareness 
of TB infection prevention. 
 
Conclusion  
We reviewed the evidence available on a global 
scale, with the aim of formulating a strategy for 
counteracting the TB/HIV disease burden in Southeast 
Asia. Contemporary evidence points out the benefit of 
early treatment and prevention of TB among PLWH. 
A diagnosis test for effective TB screening in PLWH 
is still a gap demanding further exploration in basic 
science and operational research. The two diseases, 
TB and HIV, can form an alliance in one patient, 
thereby challenging human existence and well-being. 
In response to this challenge, a completely integrated 
TB/HIV health care delivery model and local health 
system adjustment, allowing an integrated program of 
health services, is an urgent necessity. 
 
Figure 2. Three health care delivery service models adapted from the study of Kachiza C et 
al., 2010 [52] 
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